 |
 |
 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
|
[Vol.16 No.1 contents] Japanese / English |
|
| ArticleTitle | Nationwide Survey of Antifungal Drug Susceptibility of Clinical Fungal Isolates in Japan for the Japan Antifungal Surveillance Program (JASP), 2003 |
| Language | J |
| AuthorList | Hideyo Yamaguchi1), Katsuhisa Uchida1), Yayoi Nishiyama1), Katsuko Okuzumi2), Toyoko Oguri3), Keiko Adachi4), Sayoko Kawakami5), Masakazu Tosaka6), Yoshiki Misawa7), Chieko Kawashima8), Yoshiko Hori9), Toshimi Kitazawa10), Mutsumu Hayashi11), Yukie Okimura12), Association of Japan Antifungal Susceptibility Surveillance |
| Affiliation |
1) Teikyo University Institute of Medical Mycology 2) Dokkyo University Hospital 3) Juntendo University Hospital 4) Tokyo Metropolitan Geriatric Hospital 5) Teikyo University Hospital 6) Kumamoto University Hospital 7) The University of Tokyo Hospital 8) Ashikaga Red Cross Hospital 9) Okayama Saiseikai General Hospital 10) Kitkohkai General Hospital Tane Hospital 11) Jichi Medical School Ohmiya Hospital 12) Shinshu University Hospital |
| Publication | J.J.C.M.: 16 (1), 13-22, 2006 |
| Received | September 21, 2005 |
| Accepted | December 8, 2005 |
| Abstract | We evaluated the antifungal susceptibility profile of 409 recent clinical fungal isolates collected from JASP-participating nationwide hospitals during the two months, June and July 2003. Almost all isolates were Candida species (389 isolates), with fewer numbers of non-Candida yeasts (12 isolates) and molds (8 isolates). C. albicans was the most frequent species(54.5%), followed by C. glabrata (22.3%), C. tropicalis (7.1%) and C. parapsilosis (6.6%). The MIC of fluconazole (FLCZ), itraconazole (ITCZ), voriconazole (VRCZ) and flucytosine (5-FC) against Candida and other yeast species were determined by the NCCLS M27-A2 (micro) broth dilution method. Percent resistant by using the interpretive breakpoint criteria of NCCLS to FLCZ was 2.2% for C. glabrata, while no resistant isolate was seen for any other Candida species. The only exception was C. krusei, in which FLCZ-resistance was observed at a high frequency (4 of 7 isolates). For ITCZ, resistance was observed only in 1.1% of C. glabrata isolates and 3.5% of C. tropicalis isolates. Resistance to VRCZ was not observed with any species of Candida. There was no substantial difference in susceptibility to all of the four testing antifungal agents between Candida isolates from blood-related specimens and those from other clinical specimens. This study showed that the three azoles FLCZ, ITCZ and VRCZ were all active against all species of Candida, except for C. krusei frequent by resistant to FLCZ. Continued surveillance will help to identify susceptibility trends. |
| Keywords |
| Copyright © 2002 The Japanese Society for Clinical Microbiology All rights reserved. |